NFE2L2 and neoplasm: In summary, these studies further highlight YB‐1 as a potent metastatic driver in high‐risk childhood bone sarcomas by enhancing tumor cell fitness during the metastatic cascade, including through an elevated NRF2‐mediated antioxidant response.